Improved Physical Performance Parameters in Patients Taking Nicotinamide Mononucleotide (NMN): A Systematic Review of Randomized Control Trials.

Autor:	Wen J; Physical Medicine and Rehabilitation, California Northstate University College of Medicine, Elk Grove, USA., Syed B; Surgery, California Northstate University College of Medicine, Elk Grove, USA., Kim S; Internal Medicine, California Northstate University College of Medicine, Elk Grove, USA., Shehabat M; Surgery, California Northstate University College of Medicine, Elk Grove, USA., Ansari U; Neurology, California Northstate University College of Medicine, Elk Grove, USA., Razick DI; Surgery, California Northstate University College of Medicine, Elk Grove, USA., Akhtar M; Surgery, California Northstate University College of Medicine, Elk Grove, USA., Pai D; Nephrology, California Northstate University College of Medicine, Elk Grove, USA.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2024 Aug 01; Vol. 16 (8), pp. e65961. Date of Electronic Publication: 2024 Aug 01 (Print Publication: 2024).
DOI:	10.7759/cureus.65961
Abstrakt:	Nicotinamide adenine dinucleotide (NAD+) is essential in the proper function of many essential cellular processes in the human body. The purpose of this review is to investigate the effect of nicotinamide mononucleotide (NMN), a NAD+ precursor, on physical performance and evaluate the safety profile of supplementation. A systematic review search criteria following the guidelines from the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) was performed in four databases for randomized controlled trials on NMN supplementation. Study variables included title, author, publication date, study year, number of patients, dosage, mean age, mean follow-up time, pre- and post-intervention reported outcomes, and rates of complications. Ten studies, including 437 patients, with a mean age of 58.0 years (35.1 to 81.1 years) and a mean follow-up time of 9.6 weeks (4 to 12 weeks) were included in this study. NMN dosages ranged from 150 to 1200 mg/day. Mean pre-intervention grip strength (two studies) and skeletal mass index (two studies) were 29.9 kilograms (kg) (range: 21.4-40.1 kg) and 7.4 kg/m 2 (range: 6.9-7.65 kg/m 2 ), respectively. Mean post-intervention grip strength and skeletal mass index were 30.5 kg (range: 21.7-41.9 kg) and 7.4 kg/m 2 (6.8-7.64 kg/m 2 ), respectively. There were no serious adverse effects observed. Moreover, of the reported side effects, they were determined to be independent of NMN supplementation. Therefore, patients taking NMN supplementation demonstrated non-significantly improved physical performance parameters. NMN is well tolerated with no serious adverse effects observed. Competing Interests: Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. (Copyright © 2024, Wen et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu